Wall Street analyst estimates for Nuvectis Pharma, Inc. (NVCT): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases.
Valuation Ratios
| Price / Book | 52.60 |
| EV / EBITDA | -19.35 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Research & Development | 0 | $9.5M | $13.2M | $15.4M | $12.9M | $18.2M |
| Selling, General & Admin | $10000 | $3.3M | $6.0M | $7.5M | $6.9M | $9.4M |
| Operating Expenses | $10000 | $12.9M | $19.2M | $22.9M | $19.8M | $27.6M |
| Operating Income | -$10000 | -$12.9M | -$19.2M | -$22.9M | -$19.8M | -$27.6M |
| EBITDA | -$10000 | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$10000 | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$10000 | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M |
| EPS | $-0.00 | $-1.09 | $-1.51 | $-1.43 | $-1.11 | $-1.32 |
| EPS (Diluted) | $-0.00 | $-1.09 | $-1.51 | $-1.43 | $-1.11 | $-1.32 |
| Shares Outstanding (Diluted) | $12.7M | $12.7M | $12.7M | $15.6M | $17.1M | $21.8M |
Price
| Price | $21.87 |
| Market Cap | $580M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARMP · CGEN · CRDF · CYBN · IPHA · MIST · MOLN
Explore sector: Healthcare · Biotechnology
More sections of NVCT: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks